Genentech Inc.

01/24/2022 | Press release | Distributed by Public on 01/25/2022 00:01

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)